ProAdrenomedullin Assessment of Multi-Organ Failure in COvid-19 Sepsis
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 183
- 试验地点
- 8
- 主要终点
- mortality at day 28 and day 90.
研究概览
简要总结
COVID-19 is a worldwide pandemic. Around 5% of infected patients are admitted in ICU, mainly for respiratory failure. Outcome of these patients is linked to other organ failures. Optimal therapies are not defined so far. The sponsor want to assess the role of MR-ProADM as prognostic biomarker, and the impact of treatments (including supportive treatments) on MOF occurrence and outcome.
研究设计
- 研究类型
- Observational
- 观察模型
- Case Only
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Any adult patient admitted in the ICU with COVID-19 pneumonia
排除标准
- •Pregnancy
- •Legal reasons (patients under guardianship, curatorship)
- •Patient's refusal
结局指标
主要结局
mortality at day 28 and day 90.
时间窗: admission until day 90
mortality at day 28 and day 90.
Association or correlation between MR-ProADM at day 1 and day 3 and the onset of visceral failures extra respiratory in reanimation.
时间窗: comparison to day 1 and day 3
Association or correlation between MR-ProADM at day 1 and day 3 and the onset of visceral failures extra respiratory in reanimation.
次要结局
- Association between MR-ProADM and mortality at day 28.(admission until day 28)
- Association or correlation between patient factor or treatment, and the onset or aggravation of visceral failures (day 3 and day 10), evolution until day 28.(admission until day 28)